372 related articles for article (PubMed ID: 27582435)
1. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer.
Dinh KT; Mahal BA; Ziehr DR; Muralidhar V; Chen YW; Viswanathan VB; Nezolosky MD; Beard CJ; Choueiri TK; Martin NE; Orio PF; Sweeney CJ; Trinh QD; Nguyen PL
J Urol; 2015 Aug; 194(2):343-9. PubMed ID: 25681290
[TBL] [Abstract][Full Text] [Related]
3. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
[TBL] [Abstract][Full Text] [Related]
4. Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Maurice MJ; Zhu H; Kiechle JE; Kim SP; Abouassaly R
J Urol; 2016 Apr; 195(4 Pt 1):919-24. PubMed ID: 26519653
[TBL] [Abstract][Full Text] [Related]
5. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
6. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.
Sundi D; Kryvenko ON; Carter HB; Ross AE; Epstein JI; Schaeffer EM
J Urol; 2014 Jan; 191(1):60-7. PubMed ID: 23770146
[TBL] [Abstract][Full Text] [Related]
7. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
8. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
10. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
[TBL] [Abstract][Full Text] [Related]
11. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
12. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Gleason score upgrading in a large African-American population.
Vora A; Large T; Aronica J; Haynes S; Harbin A; Marchalik D; Nissim H; Lynch J; Bandi G; McGeagh K; Kowalczyk K; Ghasemian R; Venkatesan K; Verghese M; Hwang J
Int Urol Nephrol; 2013 Oct; 45(5):1257-62. PubMed ID: 23864415
[TBL] [Abstract][Full Text] [Related]
14. Increasing rate of pathologic upgrading in low risk prostate cancer patients in the active surveillance era.
Davaro F; Weinstein D; Wong R; Siddiqui S; Hinyard L; Hamilton Z
Can J Urol; 2022 Apr; 29(2):11059-11066. PubMed ID: 35429423
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
16. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
[TBL] [Abstract][Full Text] [Related]
17. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
18. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database.
Turley RS; Terris MK; Kane CJ; Aronson WJ; Presti JC; Amling CL; Freedland SJ;
BJU Int; 2008 Nov; 102(9):1074-9. PubMed ID: 18778348
[TBL] [Abstract][Full Text] [Related]
19. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
20. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
